Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Core Insights - Clearside Biomedical, Inc. is advancing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS®) injection platform, which offers significant advantages in treating retinal diseases [1][6][9] Group 1: Suprachoroidal Injection Technology - The SCS Microinjector® allows for targeted delivery of various therapeutics to the macula, retina, or choroid, potentially preserving and improving vision in patients with sight-threatening eye diseases [4][6] - The suprachoroidal injection method minimizes exposure and adverse effects on the anterior segment of the eye, enhancing bioavailability to the posterior segment [16] - The technology is designed to work with both established and new formulations of medications, providing flexibility in treatment options [4][6] Group 2: CLS-AX Development - CLS-AX (axitinib injectable suspension) is being developed as a long-acting therapy for neovascular age-related macular degeneration (wet AMD) and is currently in Phase 2b clinical testing [5][10] - Preclinical studies and a Phase 1/2a trial have shown that CLS-AX is well tolerated and has an excellent safety profile, with the potential for prolonged duration and targeted delivery [5][10] - The ongoing ODYSSEY trial is expected to provide topline data in Q3 2024, focusing on patients with confirmed, active disease and allowing for multi-dosing data [10] Group 3: Market Position and Collaborations - Clearside is the only company with an FDA-approved product for suprachoroidal use and is actively pursuing partnerships to expand its SCS injection platform [9][10] - The company has reported encouraging clinical data from its licensing partners, with multiple therapies in development targeting serious ophthalmic indications [9] - The successful application of suprachoroidal injections may extend beyond steroids to include angiogenesis inhibitors and gene therapies, broadening the scope of ophthalmic treatments [16]